BioFund Management
VC Fund
Helsinki, Finland
BioFund Management is a VC fund in Helsinki focused on Biotechnology and Biopharma. BioFund was founded in Finland in 1997 by Seppo Mäkinen and Kalevi Kurkijärvi. In 2001, BioFund established an office in Copenhagen and they have since then grown into a pan-Nordic life sciences management company. Today the firm has 8 professionals in Denmark and Finland, and has invested in almost 50 companies in 9 different countries.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries BioFund Management invests in
Stages BioFund Management invests in
Countries BioFund Management invests in
Investment Focus
Industry
- Biotechnology 3 (100%)
- Biopharma 2 (67%)
- Therapeutics 2 (67%)
- Health Care 1 (33%)
- Health Diagnostics 1 (33%)
Stage
- Funding Round 2 (67%)
- Series C 1 (33%)
Country
- United States 2 (67%)
- Finland 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ipsat Therapies
|
Ipsat Therapies, a biotechnology company, develops intestinal protection systems in antibiotic treatment. It focuses on the development of products for the prevention of antibiotic resistance, antibiotic-associated diarrhea, and hospital associated infections. The company offers bioengineered enzyme, which removes the excess unabsorbed harmfulantibiotic in intestine and maintains a normal intestinal microflora. It also develops various antibiotics, including penicillin, cephalosporin, carbapenems, and fixed combination products. Ipsat Therapies Oy was founded in 1999 and is based in Helsinki, Finland. | $9M / Series C / Apr 03, 2005 | |
Kyntra Bio
|
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissuegrowth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.FibroGen's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration). | $100M / Feb 17, 2005 | |
Egalet
|
Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and hasoptimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids. | $13.3M / Sep 20, 2001 |
Co-Investors
Adage Capital Management
1 deal together
Astellas Pharma
1 deal together
Brookside Capital
1 deal together
Daiwa SMBC Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does BioFund Management invest in?
BioFund Management invests primarily in Biotechnology, Biopharma and Therapeutics startups, most often at Funding Round and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did BioFund Management last invest?
The most recent investment recorded for BioFund Management closed in Apr 2005. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
